Navigation Links
New medication treats drug-resistant prostate cancer in the laboratory
Date:6/17/2013

A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

"Our novel prostate cancer drug works by a unique mechanism of action," said study lead author Jeremy Jones, PhD, assistant professor of molecular pharmacology at City of Hope, Beckman Research Institute, in Duarte, CA. "Thus, it has the potential to treat cancers resistant to currently approved therapies."

Prostate cancer is the second-leading cause of cancer death, after lung cancer, among men in the United States, according to the American Cancer Society. The disease affects about one out of every six men, and more than 29,000 will die of prostate cancer this year alone.

An age-related disease, prostate cancer usually affects men who are 65 or older. In addition to advanced age, genes and certain environmental factors influence the development of prostate cancer, although the exact causes remain unknown.

In a healthy prostate gland, cells express a protein called androgen-receptor, or AR, which is activated by male sex hormones, or androgens, including the primary male hormone testosterone. These same receptors also play a role in promoting the growth of the abnormal cells of prostate cancer.

The drugs that are currently available to treat prostate cancer work by preventing androgen from binding to the AR. Specifically, the drugs block androgen from attaching to a certain part of the AR known as the ligand-binding domain. This domain is the part of the receptor that hormones bind to when they activate the receptor. By blocking all androgen activity, these drugs induce chemical castration.

The problem is that prostate-cancer cells usually become resistant to androgen blockage. After initially responding, these aggressive cancers develop mutations that enable them to spread, or metastasize, without the influence of androgens. For this reason, these aggressive prostate cancers are called castration-resistant.

In contrast, the study drug binds to a different part of the AR that does not require androgen, according to Jones. "Our new lead compound, pyrvinium pamoate, works by a unique mechanism that involves binding to a different site on the AR and inhibiting its activity without preventing androgen binding," he said. "We are hopeful that an optimized derivative of pyrvinium will be able to inhibit all AR activity and inhibit the growth of human prostate cancers that become resistant to other AR-targeted therapies and perhaps result in a curative metastatic prostate cancer therapy."

Investigators conducted this pre-clinical study using prostate-cancer cells in an animal model.

The National Institutes of Health's National Cancer Institute supported part of this study.


'/>"/>

Contact: Aaron Lohr
alohr@endocrine.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Forgoing Medication, for Babys Sake
2. Parents poor math skills may lead to medication errors
3. Reducing off-label use of antipsychotic medications may save money
4. Common acne medication doubles risk of eye infection
5. Misuse of over-the-counter pain medication is potential health threat
6. Genes predict if medication can help you quit smoking
7. Acne Medication May Raise Risk of Eye Infections
8. New delivery method improves efficacy of 2 common Parkinsons disease medications
9. Mount Sinai researcher finds timing of ADHD medication affect academic progress
10. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
11. Physicians dont adequately monitor patients medication adherence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Mediaplanet is ... Wound Care" campaign in USA Today, which will educate readers on how to take ... the campaign, a large focus is placed on melanoma. Dancing with the Stars professional, ...
(Date:5/26/2017)... Clara, Calif. (PRWEB) , ... May 26, 2017 ... ... announces the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware ... provides a consistent, browser-based interface for diagnostic device operations. With this platform, initializing ...
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “When the Stars ... Home” is the creation of published author Laura Weigel Douglas, an avid reader who ... in a house that sometimes feels like Green Hills Adventure Camp. She couldn’t be ...
(Date:5/26/2017)... ... , ... Water damage to the flooring of several classrooms at The Fort ... with a number of critical issues to address before students could return to classes. ... little or no disruption to class schedules. Second, the project had to comply with ...
Breaking Medicine News(10 mins):
(Date:5/11/2017)... 11, 2017  Thornhill Research Inc. ( ... an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by ... Commercial Corporation (CCC) ( Ottawa, Ontario, Canada ... administer general anesthesia to patients requiring emergency medical ... US Marine Corps have been a longtime partner ...
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
Breaking Medicine Technology: